ArticleFrontiers in aging2026
Establishment and efficacy validation of sex-age-specific diagnostic cutoffs for sarcopenia: targeting the decline inflection points of muscle health indicators in community-dwelling middle-aged and elderly.
Article in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia is an age-related condition, with existing international guidelines predominantly focusing on the elderly and lacking age-specific diagnostic criteria. This study aims to investigate the prevalence of sarcopenia among middle-aged and elderly individuals in the Community, establish reference standards for muscle health indicators stratifiedby gender and age, and analyse age-related patterns of change and the validity of diagnostic cut-offs. Methods: A cross-sectional design was employed. Between April and June 2025, 2, 631 subjects aged ≥35 years from a community in Shijiazhuang, China, were enrolled and divided into sex-specific subgroups: 35-49, 50-64, and ≥65 years. Muscle Index (SMI), grip strength, and gait speed were measured. Diagnosis was based on the AWGS 2019 criteria. Stratified cutoffs were established using the P20 method, decline inflection points analysed via LOESS, and efficacy validated through ROC curves. Results: Overall sarcopenia prevalence was 6.65% (8.44% in males, 4.75% in females), rising to 15.26% in the ≥65 age group. Muscle indicators exhibited non-linear age-related decline with sex-specific inflection points; P20 cut-off decreased with age. AUC values for all indicators exceeded 0.75 in both the 50-64 and ≥65 age groups, demonstrating sound diagnostic performance. Conclusion: This study established sex and age stratified diagnostic cut-offs for sarcopenia in community-dwelling middle-aged and elderly individuals, elucidated the decline characteristics of core muscle indicators, and provided evidence for stratified community screening and precise prevention and control. It aligns with the concept of lifelong muscle health management and offers theoretical support for age-specific interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.